Abbott India
Abbott India Limited is a Mumbai-based, publicly listed subsidiary of Abbott Laboratories that develops, manufactures, and distributes branded generic pharmaceuticals, nutritional products, diagnostic tools, and diabetes/vascular devices across India via hospital, pharmacy, and field sales channels.
- Company typePublic
- Founded1944
- HeadquartersMumbai, India
- Headcount5,001–10,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Abbott India does
Abbott India Limited is a publicly listed pharmaceutical and healthcare company (BSE/NSE listed) headquartered in Mumbai, India, operating as a subsidiary of Abbott Laboratories, USA. Incorporated in 1944 (originally as Boots Pure Drug Company) and rebranded under the Abbott name in 2002, the company has operated in India since 1910 through its parent. The company develops, manufactures, and markets branded generic pharmaceuticals across multiple therapeutic categories including women's health, gastroenterology, cardiology, metabolic disorders, primary care, neurology, and vaccines, alongside nutritional products (Similac, Ensure, Glucerna, PediaSure, Pedialyte), diagnostic tools, and diabetes and vascular medical devices (FreeStyle Libre).
Its business model centers on prescription and OTC pharmaceutical sales distributed through three primary channels: direct hospital and clinic supply, pharmacy wholesale networks, and a medical representative field force engaging healthcare professionals. Revenue is generated via one-time product sales across these channels. The company operates a manufacturing facility in Goa (Verna Industrial Area) and is governed by a board including parent-company representatives, with Kartik Rajendran as Managing Director and Munir Shaikh as Chairman. Abbott India also recently expanded into GLP-1 diabetes therapeutics through a partnership with Novo Nordisk India, commercializing semaglutide under the Extensior brand.
Q4 FY26 revenue reached Rs 1,709.5 crore (6.5% YoY growth), with EBITDA up 12.2% to Rs 480.8 crore and margin expanding 140 basis points. The company holds a market capitalization of Rs 55,437.30 crore as of June 2026 and has 71,000+ retail shareholders (13.3% stake). Abbott India serves India's healthcare market, leveraging parent-company R&D capabilities while executing localized product development, clinical studies, and distribution tailored to Indian market needs.
Abbott India firmographics
Firmographics- Name
- Abbott India
- Legal name
- Abbott India Limited
- Website
- https://abbott.co.in
- Company type
- Public
- Founded year
- 1944
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Abbott India Limited is a Mumbai-based, publicly listed subsidiary of Abbott Laboratories that develops, manufactures, and distributes branded generic pharmaceuticals, nutritional products, diagnostic tools, and diabetes/vascular devices across India via hospital, pharmacy, and field sales channels.
- Ownership category
- akta.pro rank
Abbott India industry classification
Industry- Product category
- Branded Generic Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industries
- Specialty Care Pharmaceuticals (HLAIAAAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Abbott India is headquartered
LocationHeadquarters
- HQ city
- Mumbai
- HQ country
- India
- HQ region
- Asia
Offices3 records
Markets served
Abbott India business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Branded Generic Pharmaceuticals: Sale of high-quality pharmaceutical formulations across therapeutic areas including women's health, gastroenterology, cardiology, metabolic disorders, and primary care. Revenue generated through distribution networks to healthcare providers and pharmacies across India.
- Nutritional Products: Science-based nutritional products for infants, adults, and patients with specific nutritional needs including brands like Similac, Ensure, Glucerna, PediaSure, and Pedialyte.
- Diagnostic Tools: Diagnostic products and solutions for healthcare providers
- Diabetes and Vascular Devices: Medical devices including FreeStyle Libre and other diabetes monitoring and vascular care products
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Abbott India product offering
Product offeringCore offering
Abbott India manufactures and markets science-based healthcare products across four core segments: branded generic pharmaceuticals spanning women's health, gastroenterology, cardiology, metabolic disorders, and primary care; nutritional products for infants, adults, and patients with specific dietary needs; diagnostic tools for healthcare providers; and medical devices for diabetes management and vascular care. Products are sold through direct enterprise engagement with hospitals and clinics, plus a wide pharmacy distribution network across India.
Product overview
Abbott India Limited is a publicly listed pharmaceutical company and subsidiary of Abbott Laboratories, offering a diverse portfolio of science-based healthcare products. The portfolio encompasses branded generic pharmaceuticals across multiple therapeutic categories including women's health, gastroenterology, cardiology, metabolic disorders (including diabetes), and primary care. Beyond pharmaceuticals, the company offers nutritional products, diagnostic tools, and diabetes and vascular devices. The company has recently expanded its diabetes portfolio through the launch of Extensior (semaglutide), a GLP-1 receptor agonist for advanced type 2 diabetes management, commercialized through a partnership with Novo Nordisk India. The company's products are developed, manufactured, and marketed with expertise across product development, manufacturing, sales, and customer service, with in-house development and medical teams undertaking product and clinical development tailored to the unique needs of the Indian market.
Differentiator
Problem solved
Functional benefit
Brands
- Extensior: Semaglutide brand for advanced diabetes management launched in partnership with Novo Nordisk
Products and services
- Branded Generic Pharmaceuticals
- Nutritional Products (Similac, Ensure, Glucerna, PediaSure, Pedialyte)
- Diagnostic Tools
- Diabetes and Vascular Devices
- Extensior (Semaglutide)
Quantifiable outcome
- Q4 FY26 revenue growth of 6.5% year-over-year to Rs 1,709.5 crore
- +1 more outcomes
Companies that use Abbott India
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
Abbott India technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Abbott India partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Novo Nordisk IndiacoreAbbott India announced a partnership with Novo Nordisk India to commercialize Ozempic's semaglutide under the brand name Extensior for advanced type 2 diabetes management in India. Extensior is a GLP-1 receptor agonist approved as an adjunct to diet and exercise, offering HbA1c reduction, weight-loss benefits, and cardiovascular and kidney risk reduction. This partnership strengthens Abbott's expanding diabetes portfolio as India faces over 100 million individuals living with diabetes.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Abbott India competitors and assessment
Company assessmentDirect peers
- Sun Pharmaceutical Industries: India's largest pharmaceutical company by revenue, operating across branded generics, specialty, and APIs with a similar multi-therapeutic portfolio as Abbott India. Directly comparable given overlapping therapeutic categories (cardio, GI, women's health) and India-focused GTM.
- Cipla: Major Indian pharma with strong branded generics across respiratory, cardiology, anti-infectives, and women's health; competes directly with Abbott India in chronic and primary-care segments. Multiple Abbott India directors (e.g., Prithwish Banerji) were ex-Cipla, indicating clear competitive overlap.
- Dr. Reddy's Laboratories: India-based pharma with branded generics in India plus global generics; overlapping therapeutic coverage (GI, cardio, oncology, women's health) makes it a directly comparable branded-generic peer to Abbott India.
- Mankind Pharma: Leading Indian branded-generic and OTC player with acute/chronic portfolio directly competing with Abbott India in primary care, GI, and cardiology. Highly relevant peer for India chronic-therapy share dynamics.
- Torrent Pharmaceuticals: India-focused branded-generic specialist with strong presence in cardiovascular, CNS, and gastroenterology — categories in which Abbott India also competes. Comparable scale and channel strategy.
- Lupin Limited: Major Indian pharma player in cardiovascular, diabetes, respiratory, and women's health; competes directly with Abbott India in chronic therapy segments and has comparable India distribution depth.
- Sanofi India: Indian arm of multinational Sanofi, operating in branded pharmaceuticals across diabetes, cardiology, vaccines, and consumer health; comparable MNC-subsidiary model and chronic-care portfolio versus Abbott India.
Emerging players
- Novo Nordisk India: Abbott India's partner on the Extensior (semaglutide) launch; globally a diabetes-care giant with a direct relationship and overlapping GLP-1 / insulin franchise in India. Partner and partial competitor in diabetes.
Broad incumbents
- Pfizer India: Indian subsidiary of global pharma major with branded portfolio across vaccines, oncology, and primary care; overlaps with Abbott India's vaccines build-out and primary-care offerings.
- GlaxoSmithKline Pharmaceuticals India: MNC pharma subsidiary in India with branded generics and vaccines portfolio overlapping Abbott India's anti-infectives, dermatology, and primary-care categories. Comparable MNC distribution model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Abbott India social profiles
Digital presenceAbbott India financial estimates
Financial estimateRevenue estimate
Valuation estimate
Abbott India leadership team
Management profileNumber of profiles
Profiles21 records
Abbott India funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Abbott India M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Abbott India
What does Abbott India do?
Abbott India manufactures and markets science-based healthcare products across four core segments: branded generic pharmaceuticals spanning women's health, gastroenterology, cardiology, metabolic disorders, and primary care; nutritional products for infants, adults, and patients with specific dietary needs; diagnostic tools for healthcare providers; and medical devices for diabetes management and vascular care. Products are sold through direct enterprise engagement with hospitals and clinics, plus a wide pharmacy distribution network across India.
Is Abbott India a public or private company?
Abbott India is a public company. It is classified as public and is currently operating.
When was Abbott India founded?
Abbott India was founded in 1944. It employs 5,001 to 10,000 people.
Where is Abbott India based?
Abbott India is headquartered in Mumbai, India, in the Asia region.
How does Abbott India make money?
Four revenue lines are on record. Branded Generic Pharmaceuticals are the primary driver. The others are nutritional Products, diagnostic Tools and diabetes and Vascular Devices.
Who are Abbott India's main competitors?
Direct peers on record are Sun Pharmaceutical Industries, Cipla, Dr. Reddy's Laboratories, Mankind Pharma, Torrent Pharmaceuticals, Lupin Limited and Sanofi India. Novo Nordisk India is listed as an emerging player. Broad incumbents are Pfizer India and GlaxoSmithKline Pharmaceuticals India.
Does Abbott India have an API?
No public API is recorded for Abbott India.
What industry is Abbott India in?
Abbott India's product category is Branded Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 5122.